STAT

Opinion: I hope the departure of ‘tech-savvy’ Gottlieb won’t undo progress at the FDA

Health care has a different look than it did a decade ago. @SGottliebFDA recognized the need for the agency to pivot in response to these external pressures.
Source: Justin Sullivan/Getty Images

We’re about to lose the most tech-savvy commissioner of the Food and Drug Administration in recent memory. At its core, the FDA is about keeping people safe. But Scott Gottlieb helped transform the agency’s top role from “custodian of safety” to “advocate of innovation” by pushing for progress and refusing to let outdated regulations stand in his way. I hope his replacement doesn’t backpedal to the agency’s more conservative past and undo the progress that he’s made.

Gottlieb, who on Tuesday, has left in his nearly two-year stint at the agency. Under his forward-looking direction, the FDA has proposed several frameworks to streamline health care’s adoption of new technologies and has even received industry

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks